OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany

BACKGROUND: Ozanimod, a sphingosine 1-phosphate receptor 1 and 5 modulator, was approved as a disease-modifying therapy for active relapsing-remitting multiple sclerosis (RRMS) in 2020 and for active ulcerative colitis in 2021. Long-term, real-world studies in a nonselective population are needed. O...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziemssen, Tjalf, Richter, Stephan, Mäurer, Mathias, Buttmann, Mathias, Kreusel, Boris, Poehler, Anne-Maria, Lampl, Maren, Linker, Ralf A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271678/
https://www.ncbi.nlm.nih.gov/pubmed/35832177
http://dx.doi.org/10.3389/fneur.2022.913616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271678/
https://www.ncbi.nlm.nih.gov/pubmed/35832177
http://dx.doi.org/10.3389/fneur.2022.913616

Ejemplares similares